文献速递肝病消化内镜

EUS引导下门体压力梯度测量与肝活检同步操作与临床有意义结局相关

Simultaneous EUS-guided portosystemic pressure measurement and liver biopsy sampling correlate with clinically meaningful outcomes.
PubMed 文献 · Gastrointest Endosc · 2021-12-07

该前瞻性单中心研究纳入24例疑似肝病或肝硬化患者,评估EUS引导下门体压力梯度(EUS-PSG)测量与EUS引导下肝活检同步操作的安全性和可行性。EUS-PSG测量技术成功率为96%(23/24),肝活检成功率为100%(24/24);EUS-PSG与瞬时弹性成像测得的肝硬度(P=0.011)及纤维化-4评分(P=0.026)显著相关,但与组织学纤维化分期无显著相关性(P=0.559)。

要点

  • EUS-PSG测量与EUS引导下肝活检同步操作技术成功率高(分别为96%和100%)。
  • EUS-PSG与瞬时弹性成像肝硬度(P=0.011)及纤维化-4评分(P=0.026)显著相关。
  • EUS-PSG与组织学纤维化分期无显著相关性(P=0.559),可预测临床明显门脉高压。

核心结论

  • EUS引导下门体压力梯度测量与EUS引导下肝活检同步操作均可行且安全,并与临床明显门脉高压及无创纤维化标志物相关。

研究设计与样本

  • 前瞻性单中心研究,2020年至2021年纳入24例疑似肝病或肝硬化患者。
  • EUS-PSG通过计算平均门静脉压力与平均肝静脉压力之差获得;门脉高压定义为PSG>5 mm Hg,临床显著门脉高压定义为PSG≥10 mm Hg。

主要发现

  • PSG测量技术成功率为96%(23/24),EUS引导下肝活检成功率为100%(24/24)。
  • PSG与瞬时弹性成像测得的肝硬度显著相关(P=0.011),与纤维化-4评分显著相关(P=0.026)。
  • 组织学纤维化分期与所测PSG无显著相关性(P=0.559)。
  • 发生1例轻度不良事件(腹痛)。
  • EUS-PSG可预测临床明显门脉高压。

关键数值与推荐

  • 门脉高压定义为PSG>5 mm Hg。
  • 临床显著门脉高压定义为PSG≥10 mm Hg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The measurement of the portosystemic pressure gradient (PSG) in patients with advanced liver disease is helpful to assess the severity of portal hypertension (PH) and predict adverse clinical outcomes. EUS-guided PSG (EUS-PSG) measurement is a novel tool to assess PSG in all patients with advanced liver disease. We sought to assess the safety, feasibility, and technical success of simultaneous EUS-PSG measurement and EUS-guided liver biopsy sampling using a single-center experience. METHODS: Patients with suspected liver disease or cirrhosis were enrolled prospectively from 2020 to 2021. EUS-PSG was measured by calculating the difference between the mean portal pressure and the mean hepatic vein pressure. PH was defined as PSG >5 mm Hg and clinically significant PH as PSG ≥10 mm Hg. The primary outcomes were procedural technical success rate and correlation of EUS-PSG with fibrosis stage obtained from concurrent EUS-guided liver biopsy sampling and the correlation of EUS-PSG with patients' imaging, clinical, and laboratory findings. The secondary outcome was occurrence of procedural adverse events (AEs). RESULTS: Twenty-four patients were included in the study. PSG measurement and EUS-guided liver biopsy sampling were successful in 23 patients (technical success rate of 96%) and 24 patients (100% success), respectively. Analysis revealed a significant association between both PSG and liver stiffness measured on transient elastography (P = .011) and fibrosis-4 score (P = .026). No significant correlation was found between the fibrosis stage on histology and measured PSG (P = .559). One mild AE of abdominal pain was noted. Additionally, EUS-PSG was predictive of clinically evident PH. CONCLUSIONS: Simultaneous EUS-PSG measurement and EUS-guided liver biopsy sampling were both feasible and safe and correlated with clinically evident PH and noninvasive markers of fibrosis.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hajifathalian K, Westerveld D, Kaplan A, et al. Simultaneous EUS-guided portosystemic pressure measurement and liver biopsy sampling correlate with clinically meaningful outcomes. Gastrointest Endosc. 2021. PMID: 34890694. doi:10.1016/j.gie.2021.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。